Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SpyGlass PharmaSGP -0.59%12 Market Cap is $838.54 Mil as of Aug. 11, 2026. GuruFocus rates SGP with a GF Score™ of 12/100. Among 1,419 Biotechnology companies, SpyGlass Pharma ranks better than 77.59% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). SpyGlass Pharma's share price for the quarter that ended in Jun. 2026 was $22.26. SpyGlass Pharma's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 33.44 Mil. Therefore, SpyGlass Pharma's market cap for the quarter that ended in Jun. 2026 was $744.37 Mil.
SpyGlass Pharma's quarterly market cap
increased
from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($866.25 Mil) but then
declined
from Mar. 2026 ($866.25 Mil) to Jun. 2026 ($744.37 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. SpyGlass Pharma's Enterprise Value for Today is $608.63 Mil.
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
SpyGlass Pharma Market Cap Related Terms
SpyGlass Pharma Market Cap Historical Data
* Premium members only.
The historical data trend for SpyGlass Pharma's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, SpyGlass Pharma's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SpyGlass Pharma Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's Market Cap distribution charts can be found below:
* The bar in red indicates where SpyGlass Pharma's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
SpyGlass Pharma's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SpyGlass Pharma (SGP) has a Market Cap of $838.54 Mil as of Aug. 11, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SpyGlass Pharma and its competitors. According to the industry distribution chart, SpyGlass Pharma ranks #318 out of 1419 companies in the Biotechnology industry, placing it in the top 22.4%.
Is SpyGlass Pharma's Market Cap too high?
SpyGlass Pharma's current Market Cap is $838.54 Mil. The Biotechnology industry median Market Cap is 116.54. SpyGlass Pharma's value of $838.54 Mil is 619.6% above this industry median. Based on the distribution chart, SpyGlass Pharma ranks #318 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's Market Cap compare to RIGL and NGNE?
According to the Biotechnology industry distribution chart, SpyGlass Pharma ranks #318 out of 1419 companies for Market Cap. This places SpyGlass Pharma in the top 22% of its industry — outperforming the majority of peers. The industry median Market Cap is 116.54. SpyGlass Pharma's value of $838.54 Mil is 619.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.54, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SpyGlass Pharma's current Market Cap of $838.54 Mil is 619.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on SpyGlass Pharma and its competitors. For the Biotechnology industry, the median Market Cap is 116.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SpyGlass Pharma's current Market Cap is $838.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current Market Cap of $838.54 Mil. The current Market Cap is $838.54 Mil and 619.6% above the Biotechnology industry median of 116.54. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current Market Cap is $838.54 Mil as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score
Get the complete analysis for SGP
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGP has been successfully added to your 
